Concepts (258)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Organ Failure | 15 | 2021 | 144 | 3.390 |
Why?
|
| Plasma Exchange | 11 | 2024 | 82 | 2.180 |
Why?
|
| Sepsis | 15 | 2024 | 494 | 2.090 |
Why?
|
| Disseminated Intravascular Coagulation | 6 | 2020 | 67 | 1.550 |
Why?
|
| Thrombocytopenia | 7 | 2020 | 222 | 1.350 |
Why?
|
| von Willebrand Factor | 10 | 2023 | 185 | 1.190 |
Why?
|
| ADAM Proteins | 6 | 2023 | 84 | 1.170 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 5 | 2021 | 154 | 0.940 |
Why?
|
| Endotoxemia | 3 | 2024 | 54 | 0.840 |
Why?
|
| Thrombosis | 6 | 2022 | 503 | 0.800 |
Why?
|
| Shock, Septic | 7 | 2020 | 147 | 0.740 |
Why?
|
| Critical Illness | 10 | 2024 | 604 | 0.700 |
Why?
|
| Critical Care | 9 | 2021 | 669 | 0.680 |
Why?
|
| Hemolytic-Uremic Syndrome | 3 | 2020 | 32 | 0.680 |
Why?
|
| Plasmapheresis | 2 | 2012 | 31 | 0.600 |
Why?
|
| Biliary Tract Diseases | 1 | 2018 | 33 | 0.580 |
Why?
|
| ADAMTS13 Protein | 7 | 2023 | 65 | 0.550 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 2 | 2015 | 52 | 0.520 |
Why?
|
| Pediatrics | 7 | 2020 | 1205 | 0.510 |
Why?
|
| Hemodynamics | 6 | 2020 | 826 | 0.500 |
Why?
|
| Liver Transplantation | 5 | 2026 | 1105 | 0.490 |
Why?
|
| Extracorporeal Membrane Oxygenation | 4 | 2024 | 669 | 0.470 |
Why?
|
| Life Support Systems | 1 | 2015 | 5 | 0.470 |
Why?
|
| Liver Diseases | 1 | 2018 | 381 | 0.430 |
Why?
|
| Whole Blood Coagulation Time | 1 | 2014 | 13 | 0.420 |
Why?
|
| Factor Xa | 1 | 2014 | 15 | 0.420 |
Why?
|
| Partial Thromboplastin Time | 1 | 2014 | 44 | 0.420 |
Why?
|
| Respiration, Artificial | 3 | 2023 | 489 | 0.400 |
Why?
|
| Heparin | 1 | 2014 | 206 | 0.380 |
Why?
|
| Blood Coagulation Disorders | 2 | 2013 | 105 | 0.380 |
Why?
|
| Child, Preschool | 23 | 2026 | 14463 | 0.360 |
Why?
|
| Infant | 24 | 2026 | 12810 | 0.360 |
Why?
|
| Child | 29 | 2026 | 25298 | 0.350 |
Why?
|
| Polyethylene Glycols | 2 | 2024 | 240 | 0.350 |
Why?
|
| Drug Monitoring | 1 | 2014 | 275 | 0.340 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2012 | 185 | 0.340 |
Why?
|
| Peptide Fragments | 1 | 2015 | 762 | 0.340 |
Why?
|
| Coinfection | 1 | 2012 | 185 | 0.340 |
Why?
|
| Intensive Care Units, Pediatric | 6 | 2019 | 472 | 0.330 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2011 | 50 | 0.320 |
Why?
|
| Anticoagulants | 2 | 2014 | 581 | 0.320 |
Why?
|
| Ferritins | 2 | 2021 | 106 | 0.300 |
Why?
|
| Humans | 50 | 2026 | 127514 | 0.300 |
Why?
|
| Staphylococcus aureus | 1 | 2012 | 475 | 0.300 |
Why?
|
| Guidelines as Topic | 2 | 2020 | 197 | 0.290 |
Why?
|
| Acute Kidney Injury | 1 | 2015 | 664 | 0.280 |
Why?
|
| Biliary Atresia | 2 | 2023 | 217 | 0.280 |
Why?
|
| Staphylococcal Infections | 1 | 2012 | 565 | 0.270 |
Why?
|
| Influenza, Human | 1 | 2012 | 674 | 0.250 |
Why?
|
| Hemorrhage | 2 | 2024 | 492 | 0.250 |
Why?
|
| Cardiomyopathies | 2 | 2023 | 500 | 0.250 |
Why?
|
| Practice Guidelines as Topic | 3 | 2020 | 1277 | 0.240 |
Why?
|
| Citrulline | 2 | 2024 | 116 | 0.230 |
Why?
|
| Thrombelastography | 1 | 2026 | 65 | 0.230 |
Why?
|
| Hydrolases | 2 | 2024 | 60 | 0.220 |
Why?
|
| Blood Loss, Surgical | 1 | 2026 | 169 | 0.220 |
Why?
|
| Male | 23 | 2026 | 62896 | 0.220 |
Why?
|
| Drowning | 1 | 2025 | 47 | 0.210 |
Why?
|
| Adolescent | 14 | 2026 | 20156 | 0.210 |
Why?
|
| Nervous System Diseases | 2 | 2025 | 394 | 0.210 |
Why?
|
| Resuscitation | 4 | 2020 | 267 | 0.210 |
Why?
|
| Biomarkers | 5 | 2017 | 3253 | 0.200 |
Why?
|
| Female | 22 | 2026 | 68771 | 0.200 |
Why?
|
| Fibrin | 3 | 2022 | 64 | 0.200 |
Why?
|
| Lipopolysaccharides | 3 | 2024 | 291 | 0.190 |
Why?
|
| Arginine | 2 | 2024 | 335 | 0.190 |
Why?
|
| Platelet Adhesiveness | 2 | 2015 | 39 | 0.190 |
Why?
|
| Retrospective Studies | 13 | 2026 | 17081 | 0.180 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2021 | 17 | 0.180 |
Why?
|
| Thromboembolism | 1 | 2022 | 90 | 0.170 |
Why?
|
| Disease Models, Animal | 3 | 2024 | 4448 | 0.170 |
Why?
|
| HLA-DR Antigens | 1 | 2021 | 69 | 0.170 |
Why?
|
| Membrane Glycoproteins | 2 | 2021 | 416 | 0.170 |
Why?
|
| Patient Discharge | 1 | 2025 | 495 | 0.170 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2025 | 334 | 0.170 |
Why?
|
| Emergency Medical Services | 1 | 2025 | 410 | 0.170 |
Why?
|
| Macrophage Activation Syndrome | 2 | 2017 | 10 | 0.160 |
Why?
|
| Extracorporeal Circulation | 2 | 2018 | 53 | 0.160 |
Why?
|
| Blood Coagulation Tests | 2 | 2026 | 66 | 0.160 |
Why?
|
| Liver Cirrhosis | 3 | 2023 | 875 | 0.150 |
Why?
|
| End Stage Liver Disease | 1 | 2021 | 184 | 0.150 |
Why?
|
| Perioperative Care | 1 | 2021 | 211 | 0.150 |
Why?
|
| Phenotype | 2 | 2020 | 4309 | 0.150 |
Why?
|
| Thromboplastin | 2 | 2016 | 19 | 0.150 |
Why?
|
| Lymphocyte Activation | 1 | 2021 | 672 | 0.150 |
Why?
|
| Tracheostomy | 1 | 2021 | 215 | 0.150 |
Why?
|
| Gene Expression Regulation | 1 | 2007 | 2314 | 0.140 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2021 | 439 | 0.140 |
Why?
|
| Catheterization, Central Venous | 1 | 2019 | 140 | 0.130 |
Why?
|
| Endothelial Cells | 2 | 2023 | 506 | 0.130 |
Why?
|
| Venous Thrombosis | 1 | 2019 | 168 | 0.130 |
Why?
|
| Infant, Newborn | 8 | 2024 | 8371 | 0.130 |
Why?
|
| Patient Care Bundles | 1 | 2017 | 24 | 0.130 |
Why?
|
| Acute-On-Chronic Liver Failure | 1 | 2018 | 71 | 0.130 |
Why?
|
| Renal Replacement Therapy | 1 | 2018 | 158 | 0.130 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2017 | 112 | 0.120 |
Why?
|
| Cause of Death | 1 | 2018 | 487 | 0.120 |
Why?
|
| Recombinant Proteins | 2 | 2021 | 1295 | 0.120 |
Why?
|
| Endothelium | 1 | 2016 | 63 | 0.120 |
Why?
|
| Shiga Toxins | 1 | 2015 | 2 | 0.120 |
Why?
|
| Hemostasis | 1 | 2016 | 72 | 0.120 |
Why?
|
| Complement Inactivating Agents | 1 | 2015 | 10 | 0.120 |
Why?
|
| Organ Dysfunction Scores | 3 | 2020 | 52 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 363 | 0.120 |
Why?
|
| Complement System Proteins | 1 | 2015 | 57 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 376 | 0.120 |
Why?
|
| Vasoconstrictor Agents | 3 | 2020 | 131 | 0.110 |
Why?
|
| Case-Control Studies | 2 | 2021 | 3332 | 0.110 |
Why?
|
| Disease Progression | 2 | 2018 | 2125 | 0.110 |
Why?
|
| Risk Factors | 4 | 2023 | 10636 | 0.110 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 2014 | 70 | 0.110 |
Why?
|
| Models, Statistical | 1 | 2016 | 473 | 0.110 |
Why?
|
| Fluid Therapy | 3 | 2020 | 145 | 0.100 |
Why?
|
| Risk Assessment | 3 | 2016 | 3597 | 0.100 |
Why?
|
| Severity of Illness Index | 3 | 2024 | 2999 | 0.100 |
Why?
|
| Evidence-Based Medicine | 2 | 2020 | 631 | 0.100 |
Why?
|
| Inflammation Mediators | 1 | 2015 | 223 | 0.100 |
Why?
|
| Prognosis | 4 | 2017 | 4804 | 0.100 |
Why?
|
| Medical Audit | 1 | 2012 | 96 | 0.090 |
Why?
|
| Animals | 9 | 2024 | 33213 | 0.090 |
Why?
|
| Logistic Models | 2 | 2025 | 1791 | 0.090 |
Why?
|
| Mitochondria | 1 | 2017 | 729 | 0.090 |
Why?
|
| Treatment Outcome | 5 | 2025 | 12582 | 0.090 |
Why?
|
| Catheterization, Peripheral | 1 | 2013 | 129 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 2 | 2023 | 4513 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2015 | 542 | 0.090 |
Why?
|
| Protein Binding | 1 | 2015 | 1664 | 0.090 |
Why?
|
| Predictive Value of Tests | 2 | 2026 | 2240 | 0.080 |
Why?
|
| Respiratory Insufficiency | 1 | 2013 | 236 | 0.080 |
Why?
|
| Diagnosis, Differential | 3 | 2021 | 1868 | 0.080 |
Why?
|
| Survival Rate | 2 | 2019 | 2111 | 0.080 |
Why?
|
| Lung Diseases | 1 | 2013 | 396 | 0.080 |
Why?
|
| Swine | 2 | 2024 | 1173 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2020 | 3271 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2012 | 1207 | 0.080 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2008 | 61 | 0.070 |
Why?
|
| United States | 5 | 2017 | 11428 | 0.070 |
Why?
|
| Societies, Medical | 1 | 2012 | 766 | 0.070 |
Why?
|
| Cell Adhesion | 1 | 2008 | 299 | 0.070 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 429 | 0.070 |
Why?
|
| Heart Defects, Congenital | 1 | 2019 | 1851 | 0.070 |
Why?
|
| Glutathione | 1 | 2008 | 195 | 0.070 |
Why?
|
| Reference Values | 1 | 2008 | 687 | 0.070 |
Why?
|
| Consensus | 2 | 2020 | 558 | 0.060 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2007 | 50 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2008 | 954 | 0.060 |
Why?
|
| Mice | 3 | 2023 | 17695 | 0.060 |
Why?
|
| Interferon-gamma | 2 | 2021 | 528 | 0.060 |
Why?
|
| Protein C | 1 | 2006 | 17 | 0.060 |
Why?
|
| Child Mortality | 1 | 2005 | 20 | 0.060 |
Why?
|
| International Normalized Ratio | 1 | 2026 | 46 | 0.060 |
Why?
|
| Swimming Pools | 1 | 2025 | 12 | 0.060 |
Why?
|
| Inflammation | 2 | 2024 | 1435 | 0.060 |
Why?
|
| Interleukin-6 | 1 | 2007 | 406 | 0.060 |
Why?
|
| Platelet Count | 2 | 2016 | 132 | 0.060 |
Why?
|
| Pandemics | 2 | 2024 | 1141 | 0.060 |
Why?
|
| Patient Transfer | 1 | 2005 | 107 | 0.060 |
Why?
|
| Infant Mortality | 1 | 2005 | 176 | 0.050 |
Why?
|
| Neurologic Examination | 1 | 2025 | 194 | 0.050 |
Why?
|
| Medical Order Entry Systems | 1 | 2005 | 108 | 0.050 |
Why?
|
| Acute Disease | 1 | 2007 | 1142 | 0.050 |
Why?
|
| Propofol | 1 | 2003 | 48 | 0.050 |
Why?
|
| Hospital Mortality | 3 | 2017 | 1050 | 0.050 |
Why?
|
| Urban Population | 1 | 2025 | 276 | 0.050 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 1235 | 0.050 |
Why?
|
| Syndrome | 1 | 2006 | 1137 | 0.050 |
Why?
|
| GTP-Binding Proteins | 1 | 2023 | 160 | 0.050 |
Why?
|
| Time Factors | 3 | 2019 | 6171 | 0.050 |
Why?
|
| Hypnotics and Sedatives | 1 | 2003 | 130 | 0.050 |
Why?
|
| Fibrinolysis | 1 | 2022 | 43 | 0.050 |
Why?
|
| Age Factors | 1 | 2008 | 2814 | 0.050 |
Why?
|
| Odds Ratio | 1 | 2025 | 1218 | 0.050 |
Why?
|
| Bile Acids and Salts | 1 | 2023 | 243 | 0.040 |
Why?
|
| Biological Availability | 1 | 2021 | 137 | 0.040 |
Why?
|
| Heart Arrest | 1 | 2025 | 363 | 0.040 |
Why?
|
| Algorithms | 2 | 2020 | 1638 | 0.040 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2021 | 95 | 0.040 |
Why?
|
| Oxidoreductases | 1 | 2021 | 99 | 0.040 |
Why?
|
| Fibrinogen | 2 | 2013 | 154 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2021 | 363 | 0.040 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 200 | 0.040 |
Why?
|
| Adult | 3 | 2024 | 30609 | 0.040 |
Why?
|
| Proteome | 1 | 2021 | 275 | 0.040 |
Why?
|
| Lactic Acid | 1 | 2020 | 142 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2008 | 5160 | 0.040 |
Why?
|
| Attitude to Health | 1 | 2020 | 247 | 0.040 |
Why?
|
| Kinetics | 1 | 2021 | 1092 | 0.040 |
Why?
|
| Central Venous Catheters | 1 | 2019 | 50 | 0.040 |
Why?
|
| Cytokines | 1 | 2024 | 1326 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2018 | 88 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2021 | 1501 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2019 | 6250 | 0.030 |
Why?
|
| Anti-Infective Agents | 1 | 2020 | 264 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 285 | 0.030 |
Why?
|
| Chemokine CCL3 | 1 | 2016 | 16 | 0.030 |
Why?
|
| Matrix Metalloproteinase 8 | 1 | 2016 | 15 | 0.030 |
Why?
|
| Granzymes | 1 | 2016 | 46 | 0.030 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2019 | 369 | 0.030 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2016 | 71 | 0.030 |
Why?
|
| Texas | 1 | 2025 | 3565 | 0.030 |
Why?
|
| Cardiovascular Agents | 1 | 2017 | 85 | 0.030 |
Why?
|
| Glycocalyx | 1 | 2016 | 4 | 0.030 |
Why?
|
| Young Adult | 2 | 2021 | 9705 | 0.030 |
Why?
|
| Interleukin-8 | 1 | 2016 | 204 | 0.030 |
Why?
|
| Research Design | 1 | 2020 | 694 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2016 | 395 | 0.030 |
Why?
|
| NADPH Oxidase 2 | 1 | 2014 | 38 | 0.030 |
Why?
|
| Monitoring, Physiologic | 1 | 2017 | 372 | 0.030 |
Why?
|
| Fungemia | 1 | 2014 | 21 | 0.030 |
Why?
|
| beta-Glucans | 1 | 2014 | 20 | 0.030 |
Why?
|
| Granulocytes | 1 | 2014 | 68 | 0.030 |
Why?
|
| Proteoglycans | 1 | 2014 | 80 | 0.030 |
Why?
|
| Anesthesia | 1 | 2017 | 209 | 0.030 |
Why?
|
| Fever of Unknown Origin | 1 | 2014 | 44 | 0.030 |
Why?
|
| Opportunistic Infections | 1 | 2014 | 75 | 0.030 |
Why?
|
| Immunization, Passive | 1 | 2014 | 120 | 0.030 |
Why?
|
| NADPH Oxidases | 1 | 2014 | 108 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2016 | 649 | 0.030 |
Why?
|
| Catheter Obstruction | 1 | 2013 | 4 | 0.030 |
Why?
|
| Prothrombin Time | 1 | 2013 | 35 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2016 | 827 | 0.030 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2013 | 39 | 0.020 |
Why?
|
| Length of Stay | 1 | 2019 | 1378 | 0.020 |
Why?
|
| Autopsy | 1 | 2013 | 113 | 0.020 |
Why?
|
| Echocardiography | 1 | 2019 | 1115 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 3714 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 2016 | 467 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2014 | 784 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2013 | 303 | 0.020 |
Why?
|
| Precision Medicine | 1 | 2016 | 347 | 0.020 |
Why?
|
| ROC Curve | 1 | 2013 | 592 | 0.020 |
Why?
|
| Incidence | 1 | 2019 | 3264 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2014 | 654 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2013 | 497 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2019 | 4988 | 0.020 |
Why?
|
| Protein Multimerization | 1 | 2010 | 138 | 0.020 |
Why?
|
| Antigens, Human Platelet | 1 | 2008 | 6 | 0.020 |
Why?
|
| Glutathione Disulfide | 1 | 2008 | 20 | 0.020 |
Why?
|
| Hemorheology | 1 | 2008 | 24 | 0.020 |
Why?
|
| Integrin beta3 | 1 | 2008 | 27 | 0.020 |
Why?
|
| Cricetulus | 1 | 2008 | 87 | 0.020 |
Why?
|
| CHO Cells | 1 | 2008 | 148 | 0.020 |
Why?
|
| Pulsatile Flow | 1 | 2008 | 121 | 0.020 |
Why?
|
| Cricetinae | 1 | 2008 | 365 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 2519 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2013 | 2080 | 0.020 |
Why?
|
| Stress, Mechanical | 1 | 2008 | 172 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2008 | 425 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2008 | 405 | 0.020 |
Why?
|
| Umbilical Veins | 1 | 2007 | 64 | 0.020 |
Why?
|
| Transfection | 1 | 2008 | 948 | 0.020 |
Why?
|
| Microcirculation | 1 | 2007 | 104 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2007 | 826 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2007 | 461 | 0.010 |
Why?
|
| Contraindications | 1 | 2003 | 76 | 0.010 |
Why?
|
| United States Food and Drug Administration | 1 | 2003 | 151 | 0.010 |
Why?
|
| Safety | 1 | 2003 | 211 | 0.010 |
Why?
|
| Fatty Acids | 1 | 2003 | 351 | 0.010 |
Why?
|